What Now? What Does Ophthotech’s Disappointing Phase III Results Mean for Wet AMD, VEGF and PDGF?

KOLs, CEOs, and analysts say Ophthotech’s disappointing Fovista trials alter the landscape for companies developing new treatments for wet AMD. And all agree, the biggest losers in all of this are patients suffering from the disease.